Innovating Works
IMI2-2018-16-02
IMI2-2018-16-02: Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
Specific Challenge:The Portfolio Building Network (PBN), Pillar C of the IMI2 JU AMR Accelerator programme, will address the limited pipeline of treatments and preventions for AMR infections by enabling vibrant and nimble collaborations between EFPIA companies and small and medium-sized enterprises (SMEs) and/or academics that will advance the R&D pipeline of new and innovative agents to address AMR.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 24-10-2018.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Specific Challenge:The Portfolio Building Network (PBN), Pillar C of the IMI2 JU AMR Accelerator programme, will address the limited pipeline of treatments and preventions for AMR infections by enabling vibrant and nimble collaborations between EFPIA companies and small and medium-sized enterprises (SMEs) and/or academics that will advance the R&D pipeline of new and innovative agents to address AMR.


Scope:The project goal is to develop and advance a portfolio of anti-NTM drugs that may be used in combination with bedaquiline and cytochrome bc inhibitors to shorten treatment regimens and improve safety and efficacy. The EFPIA partner’s internal assets as well as external compounds will be profiled alone and in combination. The scope of this topic will be to progress novel lead compounds by performing medicinal chemistry optimisation, in vitro and in vivo characterisation, as well as PK, toxicology studies, formulation and CMC (chemistry, manufacturing and controls) studies. The scope also includes implementation of phase 1 studies towards the development of novel NTM candidates.


Expected Impact:The expected impact of actions selected... ver más

Specific Challenge:The Portfolio Building Network (PBN), Pillar C of the IMI2 JU AMR Accelerator programme, will address the limited pipeline of treatments and preventions for AMR infections by enabling vibrant and nimble collaborations between EFPIA companies and small and medium-sized enterprises (SMEs) and/or academics that will advance the R&D pipeline of new and innovative agents to address AMR.


Scope:The project goal is to develop and advance a portfolio of anti-NTM drugs that may be used in combination with bedaquiline and cytochrome bc inhibitors to shorten treatment regimens and improve safety and efficacy. The EFPIA partner’s internal assets as well as external compounds will be profiled alone and in combination. The scope of this topic will be to progress novel lead compounds by performing medicinal chemistry optimisation, in vitro and in vivo characterisation, as well as PK, toxicology studies, formulation and CMC (chemistry, manufacturing and controls) studies. The scope also includes implementation of phase 1 studies towards the development of novel NTM candidates.


Expected Impact:The expected impact of actions selected under this Call will be to: (1) contribute to the development of a vibrant AMR research environment in the EU and strengthen the competitiveness and industrial leadership of Europe; (2) contribute to the EU’s ambition of being a ‘best practice region’ for addressing AMR; (3) enhance the overall pipeline of medicines for patients with AMR infections and advance new and innovative agents.


ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Specific Challenge:The Portfolio Building Network (PBN), Pillar C of the IMI2 JU AMR Accelerator programme, will address the limited pipeline of treatments and preventions for AMR infections by enabling vibrant and nimble collaborations between EFPIA companies and small and medium-sized enterprises (SMEs) and/or academics that will advance the R&D pipeline of new and innovative agents to address AMR. Specific Challenge:The Portfolio Building Network (PBN), Pillar C of the IMI2 JU AMR Accelerator programme, will address the limited pipeline of treatments and preventions for AMR infections by enabling vibrant and nimble collaborations between EFPIA companies and small and medium-sized enterprises (SMEs) and/or academics that will advance the R&D pipeline of new and innovative agents to address AMR.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Amortizaciones.
Activos.
Otros Gastos.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Please read carefully all provisions stated below before the preparation of your application.
The IMI2 JU 16th Call for proposals topics text as well as the Call Conditions are available here.  
The budget breakdown for this Call is given at the end of the Call topics text, in the Call Conditions section, as well as the following information : 
1.   Eligible countries: described in article 10(2) of the Rules for participation in Horizon 2020 and in article 1 of the Commission Delegated Regulation related to IMI JU.
2.   Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award. See also the Commission Delegated Regulation related to IMI JU.
Proposal page limits and layout: Please refer to Part B of the proposal template in the submission tool below.
3.   Evaluation:
Submission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the IMI2 Manual for submission, evaluation and grant award. See also the proposal templates for your specific action in section 5, below.
4.   Indicative time for evaluation and grant agreement:
Notification of outcomes of the evaluation: maximum 5 months from deadline for submitting proposals.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants. Please read carefully all provisions stated below before the preparation of your application.
The IMI2 JU 16th Call for proposals topics text as well as the Call Conditions are available here.  
The budget breakdown for this Call is given at the end of the Call topics text, in the Call Conditions section, as well as the following information : 
1.   Eligible countries: described in article 10(2) of the Rules for participation in Horizon 2020 and in article 1 of the Commission Delegated Regulation related to IMI JU.
2.   Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award. See also the Commission Delegated Regulation related to IMI JU.
Proposal page limits and layout: Please refer to Part B of the proposal template in the submission tool below.
3.   Evaluation:
Submission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the IMI2 Manual for submission, evaluation and grant award. See also the proposal templates for your specific action in section 5, below.
4.   Indicative time for evaluation and grant agreement:
Notification of outcomes of the evaluation: maximum 5 months from deadline for submitting proposals.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
5.   Proposal templates, evaluation forms and model grant agreements (MGA):
IMI2 Research and Innovation Action (IMI2-RIA) and Innovation Action (IMI2-IA):
Proposal templates are available after entering the submission tool
Standard evaluation form
IMI2 Model Grant Agreement
Clinical trial template – the Clinical Trial template is compulsory at stage 2 only !
IMI2 Model Grant Agreement
 
6.   Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the H2020 main Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
Members of consortium are required to conclude a consortium agreement prior to the signature of the grant agreement.
7. Additional documents:
Summary of the most relevant provisions for participating in IMI2 actions
3rd Amended IMI2 Amended Annual Work Plan 2018
IMI2 Regulators Guidance tool for researchers
IMI JU derogation to H2020 Rules for Participation  
Horizon 2020 Rules for Participation 
Horizon 2020 Regulation of Establishment
Horizon 2020 Specific Programme
 
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-JTI-IMI2-2018-16-single-stage Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs Specific Challenge:The Portfolio Building Network (PBN), Pillar C of the IMI2 JU AMR Accelerator programme, will address the limited pipelin...
Sin info.
IMI2-2018-15-03 Microenvironment imposed signatures in tissue and liquid biopsies in immune- mediated diseases
en consorcio: Specific Challenge:Biological therapies have provided significant therapeutic benefit to patients with immuno-inflammatory diseases, but man...
Cerrada hace 6 años | Próxima convocatoria prevista para el mes de
IMI2-2018-16-06 Functional Ethionamide boosters: a novel combination for tuberculosis therapy
en consorcio: Specific Challenge:The Portfolio Building Network (PBN), Pillar C of the IMI2 JU AMR Accelerator programme, will address the limited pipelin...
Cerrada hace 6 años | Próxima convocatoria prevista para el mes de
IMI2-2018-16-02 Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
en consorcio: Specific Challenge:The Portfolio Building Network (PBN), Pillar C of the IMI2 JU AMR Accelerator programme, will address the limited pipelin...
Cerrada hace 6 años | Próxima convocatoria prevista para el mes de
IMI2-2018-15-06 Digital endpoints in neurodegenerative and immune-mediated diseases
en consorcio: Specific Challenge:Neurodegenerative movement disorders (NMD) and immune mediated inflammatory diseases (IMID) can cause considerable disabi...
Cerrada hace 6 años | Próxima convocatoria prevista para el mes de
IMI2-2018-15-02 Blockchain Enabled Healthcare
en consorcio: Specific Challenge: The pharmaceutical value chain and the extended healthcare ecosystem have many areas that suffer from complexity, a la...
Cerrada hace 6 años | Próxima convocatoria prevista para el mes de